

CORRECTION

Open Access



Correction: Updated safety results from phase 3 lecanemab study in early Alzheimer's disease

Lawrence S. Honig^{1*}, Marwan N. Sabbagh², Christopher H. van Dyck³, Reisa A. Sperling⁴, Steven Hersch⁵, Andre Matta⁵, Luigi Giorgi⁶, Michelle Gee⁶, Michio Kanekiyo⁵, David Li⁵, Derk Purcell⁷, Shobha Dhadha⁵, Michael Irizarry⁵ and Lynn Kramer⁵

Correction: *Alz Res Therapy* 16, 105 (2024)
<https://doi.org/10.1186/s13195-024-01441-8>

Following publication of the original article [1], several typographical errors were observed:

- In Table 2, recurrent ARIA-E for ApoE carriers should be 3.8% (not 11.7%).
- In Table 2, there were several incorrect indentations for several rows (old and updated versions of Table 2 are presented below).
- There are two places on page 6 where 'ARIA-E' should be 'ARIA'.

- In Table 5, the asterisk in right column should be a superscript '1'. The footnote should have an end parenthesis at end of the footnote sentence below the table.

Moreover, Supplementary material 1 (.docx) has been replaced with its pdf version with modification in Table S4 - ID21 (the participant should be "male" instead of "female").

The online version of the original article can be found at <https://doi.org/10.1186/s13195-024-01441-8>.

*Correspondence:

Lawrence S. Honig
lh456@cumc.columbia.edu

¹Columbia University Irving Medical Center, NYS Center of Excellence for Alzheimer's Disease, Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Gertrude H. Sergievsky Center (PH19), & Department of Neurology, Columbia University Vagelos College of Physicians & Surgeons, 630 West 168th Street (P&S UNIT 16), New York, NY 10032-3795, USA

²Barrow Neurological Institute, Phoenix, AZ 85013, USA

³Yale School of Medicine, New Haven, CT, USA

⁴Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

⁵Eisai Inc., Nutley, NJ, USA

⁶Eisai Co., Ltd, Hatfield, UK

⁷Clario, Philadelphia, PA, USA



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

The old version of Table 2:

Table 2 Adverse events and ARIA in Clarity Core and Core + OLE

	Core		Core + OLE
	Placebo (N = 897) n/N (%)	Lecanemab (N = 898) n/N (%)	Lecanemab (N = 1612) n/N (%)
Any adverse event	735 (81.9)	798 (88.9)	1389 (86.2)
Deaths	7 (0.8)	6 (0.7)	16 (1.0)*
Serious adverse event (SAE)	101 (11.3)	126 (14.0)	241 (15.0)
SAE with ARIA-E	0	7 (0.8)	18 (1.1)
SAE with ARIA-H	0	2 (0.2)	10 (0.6)
SAE with infusion-related reactions	0	11 (1.2)	20 (1.2)
Treatment-related adverse event	197 (22.0)	401 (44.7)	721 (44.7)
Adverse event leading to drug withdrawal	26 (2.9)	62 (6.9)	124 (7.7)
ARIA-E	15/897 (1.7)	113/898 (12.6)	219/1612 (13.6)
ARIA-E by ApoE4 genotype			
ApoE4 noncarrier	1/286 (0.3)	15/278 (5.4)	32/496 (6.5)
ApoE4 carrier	14/611 (2.3)	98/620 (15.8)	187/1116 (16.8)
ApoE4 heterozygote	9/478 (1.9)	52/479 (10.9)	101/867 (11.6)
ApoE4 homozygote	5/133 (3.8)	46/141 (32.6)	86/249 (34.5)
Symptomatic ARIA-E	0	25/898 (2.8)	54/1612 (3.3)
ApoE4 noncarrier	0	4/278 (1.4)	8/496 (1.6)
ApoE4 carrier	0	21/620 (3.4)	46/1116 (4.1)
ApoE4 heterozygote	0	8/479 (1.7)	18/867 (2.1)
ApoE4 homozygote	0	13/141 (9.2)	28/249 (11.2)
Recurrent ARIA-E	1 (0.1)	28 (3.1)	46/1612 (2.9)
ApoE4 noncarrier	0/286 (0)	1/278 (0.4)	4/496 (0.8)
ApoE4 carrier	1/611 (0.2)	27/620 (4.4)	42/1116 (11.7)
ApoE4 heterozygote	0/478 (0)	7/479 (1.5)	18/867 (2.1)
ApoE4 homozygote	1/133 (0.8)	20/141 (14.2)	24/249 (9.6)
ARIA-H	80 (8.9)	152 (16.9)	298/1612 (18.5)
Microhemorrhage	68 (7.6)	126 (14.0)	258/1612 (16.0)
Superficial siderosis	21 (2.3)	50 (5.6)	96/1612 (6.0)
Intracerebral hemorrhage	1 (0.1)	5 (0.6)	8/1612 (0.5)
Symptomatic ARIA-H	2 (0.2)	11 (1.2)	27/1612 (1.7)
ARIA-H by ApoE4 genotype			
ApoE4 noncarrier, n/N (%)	11/286 (3.8)	32/278 (11.5)	59/496 (11.9)
ApoE4 carrier, n/N (%)	69/611 (11.3)	120/620 (19.4)	239/1116 (21.4)
ApoE4 heterozygote, n/N (%)	41/478 (8.6)	66/479 (13.8)	140/867 (16.1)
ApoE4 homozygote, n/N (%)	28/133 (21.1)	54/141 (38.3)	99/249 (39.8)
Isolated ARIA-H	69 (7.7)	78 (8.7)	146 (9.1)
Microhemorrhage	63 (7.0)	60 (6.7)	119 (7.4)
Superficial siderosis	13 (1.4)	23 (2.6)	39 (2.4)
Isolated intracerebral hemorrhage	1 (0.1)	4 (0.4)	5 (0.3)
Symptomatic isolated ARIA-H	2 (0.2)	4 (0.4)	6 (0.4)
Isolated ARIA-H by ApoE4 genotype			
ApoE4 noncarrier, n/N (%)	10/286 (3.5)	22/278 (7.9)	38/496 (7.7)
ApoE4 carrier, n/N (%)	59/611 (9.7)	56/620 (9.0)	108/1116 (9.7)
ApoE4 heterozygote, n/N (%)	35/478 (7.3)	39/479 (8.1)	76/867 (8.8)
ApoE4 homozygote, n/N (%)	24/133 (18.0)	17/141 (12.1)	32/249 (12.9)

*The 16 deaths included 6 from Core, 9 from OLE, and one death that occurred > 30 days after last dose

The updated version of Table 2:

Table 2 Adverse events and ARIA in Clarity Core and Core + OLE

	Core		Core + OLE
	Placebo (N = 897) n/N (%)	Lecanemab (N = 898) n/N (%)	Lecanemab (N = 1612) n/N (%)
Any adverse event	735 (81.9)	798 (88.9)	1389 (86.2)
Deaths	7 (0.8)	6 (0.7)	16 (1.0)*
Serious adverse event (SAE)	101 (11.3)	126 (14.0)	241 (15.0)
SAE with ARIA-E	0	7 (0.8)	18 (1.1)
SAE with ARIA-H	0	2 (0.2)	10 (0.6)
SAE with infusion-related reactions	0	11 (1.2)	20 (1.2)
Treatment-related adverse event	197 (22.0)	401 (44.7)	721 (44.7)
Adverse event leading to drug withdrawal	26 (2.9)	62 (6.9)	124 (7.7)
ARIA-E	15/897 (1.7)	113/898 (12.6)	219/1612 (13.6)
ARIA-E by ApoE4 genotype			
ApoE4 noncarrier	1/286 (0.3)	15/278 (5.4)	32/496 (6.5)
ApoE4 carrier	14/611 (2.3)	98/620 (15.8)	187/1116 (16.8)
ApoE4 heterozygote	9/478 (1.9)	52/479 (10.9)	101/867 (11.6)
ApoE4 homozygote	5/133 (3.8)	46/141 (32.6)	86/249 (34.5)
Symptomatic ARIA-E	0	25/898 (2.8)	54/1612 (3.3)
ApoE4 noncarrier	0	4/278 (1.4)	8/496 (1.6)
ApoE4 carrier	0	21/620 (3.4)	46/1116 (4.1)
ApoE4 heterozygote	0	8/479 (1.7)	18/867 (2.1)
ApoE4 homozygote	0	13/141 (9.2)	28/249 (11.2)
Recurrent ARIA-E	1 (0.1)	28 (3.1)	46/1612 (2.9)
ApoE4 noncarrier	0/286 (0)	1/278 (0.4)	4/496 (0.8)
ApoE4 carrier	1/611 (0.2)	27/620 (4.4)	42/1116 (3.8)
ApoE4 heterozygote	0/478 (0)	7/479 (1.5)	18/867 (2.1)
ApoE4 homozygote	1/133 (0.8)	20/141 (14.2)	24/249 (9.6)
ARIA-H	80 (8.9)	152 (16.9)	298/1612 (18.5)
Microhemorrhage	68 (7.6)	126 (14.0)	258/1612 (16.0)
Superficial siderosis	21 (2.3)	50 (5.6)	96/1612 (6.0)
Intracerebral hemorrhage	1 (0.1)	5 (0.6)	8/1612 (0.5)
Symptomatic ARIA-H	2 (0.2)	11 (1.2)	27/1612 (1.7)
ARIA-H by ApoE4 genotype			
ApoE4 noncarrier, n/N (%)	11/286 (3.8)	32/278 (11.5)	59/496 (11.9)
ApoE4 carrier, n/N (%)	69/611 (11.3)	120/620 (19.4)	239/1116 (21.4)
ApoE4 heterozygote, n/N (%)	41/478 (8.6)	66/479 (13.8)	140/867 (16.1)
ApoE4 homozygote, n/N (%)	28/133 (21.1)	54/141 (38.3)	99/249 (39.8)
Isolated ARIA-H	69 (7.7)	78 (8.7)	146 (9.1)
Microhemorrhage	63 (7.0)	60 (6.7)	119 (7.4)
Superficial siderosis	13 (1.4)	23 (2.6)	39 (2.4)
Isolated intracerebral hemorrhage	1 (0.1)	4 (0.4)	5 (0.3)
Symptomatic isolated ARIA-H	2 (0.2)	4 (0.4)	6 (0.4)
Isolated ARIA-H by ApoE4 genotype			
ApoE4 noncarrier, n/N (%)	10/286 (3.5)	22/278 (7.9)	38/496 (7.7)
ApoE4 carrier, n/N (%)	59/611 (9.7)	56/620 (9.0)	108/1116 (9.7)
ApoE4 heterozygote, n/N (%)	35/478 (7.3)	39/479 (8.1)	76/867 (8.8)
ApoE4 homozygote, n/N (%)	24/133 (18.0)	17/141 (12.1)	32/249 (12.9)

*The 16 deaths included 6 from Core, 9 from OLE, and one death that occurred > 30 days after last dose

The original article [1] has been updated.

Published online: 10 July 2024

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

1. Honig LS, Sabbagh MN, van Dyck CH, et al. Updated safety results from phase 3 lecanemab study in early Alzheimer's disease. *Alz Res Therapy*. 2024;16:105. <https://doi.org/10.1186/s13195-024-01441-8>